ALHC vs HUM: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
HUM is the larger of the two ($43.69B market cap): the incumbent the market prices for continued execution (22.08x forward earnings, beta 0.72). ALHC is the smaller challenger ($3.08B), priced similarly on forward earnings (19.73x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ALHC vs HUM: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ALHC | HUM | What it tells you |
|---|---|---|---|
| Market cap | $3.08B | $43.69B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 19.73 | 22.08 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 78.16 | 34.36 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.05 | 0.72 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 15% of range | 76% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how ALHC and HUM affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALHC and HUM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALHC and HUM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Alignment Healthcare (ALHC) do?
Alignment Healthcare operates Medicare Advantage health plans, mostly in California and a handful of other states, serving roughly 285,000 members as of early 2026. Its model pairs a customized clinical care approach with a purpose-built technology platform (branded AVA) and local provider partnerships, aiming to deliver better health outcomes at lower cost than legacy insurers. High Star Ratings (generally in the 4 to 5 range) are central to the thesis because they drive bonus payments and help attract members.
What does Humana (HUM) do?
Humana Inc. is a Louisville-based health and well-being company best known as one of the two largest Medicare Advantage insurers in the country, alongside UnitedHealth. Its Insurance segment covers roughly 7.1 million individual and group Medicare Advantage members as of early 2026, plus Medicaid, military (TRICARE), and pharmacy-benefit members. The core economics turn on the medical loss ratio, the share of premium dollars paid out as medical claims, and on CMS star ratings, which determine quality-bonus payments that fund richer plan benefits.
ALHC vs HUM: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ALHC drivers: Membership growth engine; Margin and profitability inflection.
- HUM drivers: Demographic tailwind in Medicare Advantage; CenterWell healthcare services.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Medical costs are the dominant swing factor: a reversion in utilization, an unexpected cost shock, or unfavorable risk-adjustment changes could quickly compress the thin margins. For HUM, the medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure.
ALHC or HUM: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALHC if you believe its drivers more; HUM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALHC and HUM guides.
ALHC vs HUM: the full fundamentals
ALHC. ALHC recently crossed into profitability, posting ~$11 million of net income in Q1 2026 versus a prior-year loss, which leaves the trailing P/E extremely high (well over 100x) and makes the stock look expensive on current earnings. The bull case rests on forward growth and margin expansion rather than trailing profits. Shares traded around the low-to-mid $20s in mid-2026, near 52-week highs.
HUM. These figures are approximate and tied to the June 2026 asOf date; insurer earnings can move sharply quarter to quarter with the medical-cost trend, and the trailing P/E looks high mainly because recent profits are depressed. Check Humana's latest filings and a current quote before relying on any single number.
Headline figures (approximate, JULY 2026): ALHC shows revenue (ttm) ~$4.5B, q1 2026 revenue (yoy) ~$1.24B (+33%), 2026 revenue guidance ~$5.14B to $5.19B, adjusted ebitda (2026 guide) ~$133M to $163M; HUM shows revenue (ttm) ~$130 billion, adjusted eps (2026 guidance) ~$9.00 or more, medical loss ratio (2026 outlook) ~92.75%, dividend yield ~1.5%.
The bottom line: ALHC vs HUM
ALHC and HUM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALHC and HUM exposure against your real portfolio. It is not an investment adviser.
Wondering how ALHC or HUM fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Alignment Healthcare with AI
Connect the broker you already use and ask Walnut's AI how ALHC fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between ALHC and HUM?
+
Alignment Healthcare operates Medicare Advantage health plans, mostly in California and a handful of other states, serving roughly 285,000 members as of early 2026. Humana Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ALHC or HUM the better stock?
+
Neither is universally better. HUM is the larger incumbent; ALHC is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ALHC or HUM?
+
On forward P/E (as of August 2026), ALHC trades at 19.73x and HUM at 22.08x, so ALHC is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ALHC and HUM?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ALHC vs HUM?
+
ALHC: Medical costs are the dominant swing factor: a reversion in utilization, an unexpected cost shock, or unfavorable risk-adjustment changes could quickly compress the thin margins. Membership is geographically concentrated (heavy California exposure), so state-level competition or regulatory shifts carry outsized impact. CMS policy on Star Ratings, rate benchmarks, and risk coding directly affects revenue and bonus payments. The valuation is demanding, with a trailing P/E in the hundreds, so any growth deceleration or margin miss could drive a sharp de-rating. It also competes against far larger, better-capitalized insurers that can pressure pricing and benefits. HUM: The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure. Star ratings are a second lever, since a slip in ratings reduces CMS quality-bonus payments and can force benefit cuts that hurt retention; Humana's ratings softened heading into 2026. Medicare Advantage reimbursement and broader healthcare policy are set by the government and can change rate updates, risk-adjustment rules, or audit intensity. Finally, aggressive membership growth or repricing can pressure profitability or cause member attrition if benefits are trimmed too far.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ALHC or HUM; figures are approximate and dated (as of August 2026). Verify current data before investing.